exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275127 RNA Name: hsa-miR-92a-3p RNA Type: miRNA Chromosome: chrX Starnd: - Coordinate: Start Site(bp): 134169544 End Site(bp): 134169565 External Links: hsa-miR-92a-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MAZ chr16 29806106 29811164 + RPS8 chr1 44775251 44778779 + ESRP1 chr8 94641074 94707466 + PTPRZ1 chr7 121873089 122062036 + YIPF3 chr6 43511832 43516985 - SEC63 chr6 107867756 107958208 - NPM1 chr5 171387116 171411137 + USP21 chr1 161159450 161165723 + ZNF330 chr4 141220887 141234697 + HBE1 chr11 5268345 5505652 - EHMT2 chr6 31879759 31897687 - PITPNA chr17 1517718 1562792 - RBBP5 chr1 205086142 205122015 - PNKD chr2 218270392 218346793 + SMC1A chrX 53374149 53422728 - RWDD1 chr6 116571409 116597675 + GLCE chr15 69160584 69272217 + CEP89 chr19 32875925 32971991 - PPP3CB chr10 73436428 73496024 - HMGB1 chr13 30456704 30617597 - KLF4 chr9 107484852 107490482 - MRPS16 chr10 73248843 73252693 - TCP1 chr6 159778498 159789703 - EZR chr6 158765741 158819368 - PSMB8 chr6 32840717 32844679 - RPL17-C18orf32 chr18 49481681 49492479 - OGFOD1 chr16 56451521 56479104 + MCM3 chr6 52264014 52284881 - EIF4G2 chr11 10797050 10808940 - RPL13A chr19 49487554 49492308 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001005 chr2 53921020 53978078 - hsa_circ_0001414 chr4 56277780 56284152 + hsa_circ_0000126 chr1 150997086 150999803 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005394.2 chr19 28435388 28727680 - AC074117.1 chr2 27356246 27367622 + AC130650.2 chr16 14150833 14153235 + DAPK1-IT1 chr9 87553454 87554459 + LINC01128 chr1 825138 859446 + MALAT1 chr11 65497688 65506516 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + PITPNA-AS1 chr17 1516931 1518096 + PURPL chr5 27217714 27496994 + SNHG5 chr6 85650491 85678932 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.